Empagliflozin Favorably Reshaped LVs in HFrEF Sufferers
Therapy with the SGLT2 inhibitor empagliflozin led to predominant reductions in each left ventricular conclude systolic and diastolic volumes in two fair randomized studies of sufferers with coronary heart failure with reduced ejection fraction. These results provide predominant new evidence…